- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05047653
RALE Versus CORADS/CT-Severity Score in COVID-19 (RALE-CORADS)
The Prognostic Value of the Abnormalities on the Chest Radiography Versus the Chest Computed Tomography in Critically Ill COVID-19 Patients - Protocol for a National Study Comparing the RALE With the CORADS and CT-Severity Score
Rationale Patients with severe coronavirus disease 2019 (COVID-19) frequently fulfill the criteria for acute respiratory distress syndrome (ARDS), with extensive and bilateral abnormalities on the chest radiography (CXR) and the chest computed tomography (CT) abnormalities. The 'Radiographic Assessment of Lung Edema' (RALE) score, the 'COVID-19 Reporting and Data System' (CO-RADS) score, and the 'CT severity score' may all have prognostic value in critically ill patients with acute respiratory failure due to COVID-19.
Objectives To compare the prognostic value of the RALE score, the CO-RADS score and the CT severity score in critically ill patients with ARDS due to COVID-19.
Hypotheses The RALE score, the CO-RADS score and the CT severity score have prognostic value (primary). The RALE score, the CO-RADS score and the CT severity score correlate well.
Study design National, retrospective observational study. Study population Critically ill COVID-19 patients with acute respiratory failure, who received at least one CXR and one chest CT scan during critical illness.
Method CXRs are visually scored by two independent investigators, using the RALE score approach. Chest CT scans are scored by an independent radiologist, using the CO-RADS score and the CT severity score. Demographic, ventilation and outcome data are captured from the hospital systems.
Main study parameters/endpoints ICU mortality (primary) and hospital-, 28-, 90-mortality, the number of days alive and free from invasive ventilation, duration of ventilation in survivors, and length of stay in ICU and hospital.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness Participants will not directly benefit from participation, but burden is absent. The CRX and chest CT scans have already been obtained as part of routine clinical care. Collecting CXR for RALE scoring and chest CT scans for CO-RADS and CT severity scoring, clinical and outcome data is of no harm for individual patients.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Amsterdam, Nederländerna
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- admitted to the intensive care unit of the Amsterdam UMC, location 'AMC', between March 1, 2020 and May 31, 2020 (the first 3 months of the first wave of the national outbreak in the Netherlands) and between October 1, 2020 and December 31, 2020 (the first 3 months of the second wave in the Netherlands);
- RT-PCR confirmed coronavirus diseases 2019 (COVID-19); and
- having had received at least one chest radiograph (CXR) and one adjacent chest computed tomography (CT) scan during the period a patient was having acute respiratory failure.
Exclusion Criteria:
- Age < 18 years.
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
ICU mortality
Tidsram: 90 days
|
The ICU mortality with a maximum of 90 days
|
90 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
hospital mortality
Tidsram: 90 days
|
The hospital mortality with a maximum of 90 days
|
90 days
|
|
28-day mortality
Tidsram: 28 days
|
The 28-day mortality
|
28 days
|
|
90-day mortality
Tidsram: 90 days
|
The 90-day mortality
|
90 days
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RALE-CORADS
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på COVID-19 lunginflammation
-
Qilu Pharmaceutical Co., Ltd.RekryteringSjukhusförvärvad bakteriell pneumoni och ventilatorassocierad bakteriell pneumoniKina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Har inte rekryterat ännuSjukhusförvärvad bakteriell pneumoni/Ventilatorassocierad bakteriell pneumoniKina
-
University Hospital, LilleHar inte rekryterat ännuPneumoni, ventilatorassocierad Vårdrelaterad pneumoni Andning, artificiell
-
First Teaching Hospital of Tianjin University of...Har inte rekryterat ännu
-
PfizerAktiv, inte rekryterandeCovid-19 | Coronaviruss sjukdom 2019 (COVID-19) | Covid-19 infektion | Covid-19 vacciner | SARS-CoV-2-infektion, COVID19 | Covid-19-vaccination | SARS-CoV-2-infektion, COVID-19 | COVID-19 (Coronavirus sjukdom 2019) | COVID-19 SARS-CoV-2-infektionFörenta staterna
-
The Children's Hospital of Zhejiang University...Shanghai Feihong Medical Technology Co., Ltd.; Zhuhai Huaguang Medical...Har inte rekryterat ännu
-
PfizerRekryteringLuftvägssjukdomar | Covid-19 | Lunginflammation | Lungsjukdomar | Coronavirus-sjukdom 2019 | Coronaviruss sjukdom 2019 (COVID-19) | Covid-19 infektion | Övre luftvägsinfektioner | Luftvägsinfektion | COVID-19 (Coronavirus sjukdom 2019) | COVID-19 SARS-CoV-2-infektionBelgien
-
ModeX Therapeutics, An OPKO Health CompanyRekryteringCOVID 19 | COVID-19 (Prevention)Förenta staterna
-
Beijing Continent Pharmaceutical Co, Ltd.Sun Yat-sen UniversityRekryteringStrålningsinducerad lungskada | Immunrelaterad pneumoniKina
-
Shanghai Public Health Clinical CenterHar inte rekryterat ännu
Kliniska prövningar på RALE score vs. severity score
-
NYU Langone HealthAvslutadPrematuritetsanemi (AOP)Förenta staterna